News

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Cryo-electron microscopy allows structural biologists to look at the most minute building blocks of life. We celebrated the opening of the joint Core Facility and the corresponding research building of Charité – Universitätsmedizin Berlin and the Max Delbrück Center with a symposium.

Whether aggressive cancer cells can spread unchecked depends, to no small degree, on their cellular neighborhood. Fabian Coscia wants to analyze exactly what happens at the proteome level during this interaction. He has now been selected for a €1 million-plus grant from the European Research Council (ERC) to pursue this research.

Bartter syndrome type 3 is the result of several structural variants in the genome. By using long-read sequencing, Janine Altmüller and her team from the Max Delbrück Center, the BIH and University Hospital Cologne mapped out the rare disease in unprecedented detail. They have now reported their findings in “Genome Medicine.”

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying. Researchers led by Claus Scheidereit at the Max Delbrück Center have now described in Cell Chemical Biology two new compounds that block this escape route.

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall.

Some T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants. Scientists from BIH and Max Delbrück Center have now published their findings in the journal “Nature Genetics”.

Biochemist and physician Leif S. Ludwig of the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has been named a recipient of the 2023 Heinz Maier-Leibnitz Prize, as the German Research Foundation (DFG) announced on June 27th.